Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tackling DNA damage repair mechanisms—a promising molecular informed therapeutic approach in pancreatic ductal adenocarcinoma

Tackling DNA damage repair mechanisms—a promising molecular informed therapeutic approach in... Summary Molecular targeted therapies in pancreatic ductal adenocarcinoma (PDAC) lag behind treatment options in other tumor entities. The POLO trial has provided promising preliminary data for targeting gBRCA in PDAC by the poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib. This review tries to show further potential approaches to exploit faulty DNA repair mechanisms beyond gBRCA and olaparib. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Tackling DNA damage repair mechanisms—a promising molecular informed therapeutic approach in pancreatic ductal adenocarcinoma

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/tackling-dna-damage-repair-mechanisms-a-promising-molecular-informed-goUWNUPWiQ
Publisher
Springer Journals
Copyright
2020 Springer-Verlag GmbH Austria, part of Springer Nature
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-020-00658-1
Publisher site
See Article on Publisher Site

Abstract

Summary Molecular targeted therapies in pancreatic ductal adenocarcinoma (PDAC) lag behind treatment options in other tumor entities. The POLO trial has provided promising preliminary data for targeting gBRCA in PDAC by the poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib. This review tries to show further potential approaches to exploit faulty DNA repair mechanisms beyond gBRCA and olaparib.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Dec 1, 2020

Keywords: oncology; medicine/public health, general

References

  • Krebserkrankungen in Österreich 2020
    citation_title=Krebserkrankungen in Österreich
  • FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
    T Conroy, F Desseigne, M Ychou, O Bouché, R Guimbaud, Y Bécouarn
  • Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
    DDV Hoff, T Ervin, FP Arena, EG Chiorean, J Infante, M Moore
  • NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors
    A Wang-Gillam, RA Hubner, JT Siveke, DDV Hoff, B Belanger, FA Jong
  • Erlotinib plus Gemcitabine compared with Gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group
    MJ Moore, D Goldstein, J Hamm, A Figer, JR Hecht, S Gallinger
  • KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer
    J Cicenas, K Kvederaviciute, I Meskinyte, E Meskinyte-Kausiliene, A Skeberdyte, J Cicenas
  • The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings
    T Helleday
  • Genomic methods identify homologous recombination deficiency in pancreas Adenocarcinoma and optimize treatment selection. Clin
    W Park, J Chen, JF Chou, AM Varghese, KH Yu, W Wong
  • Maintenance Olaparib for Germline BRCA-mutated metastatic pancreatic cancer
    T Golan, P Hammel, M Reni, EV Cutsem, T Macarulla, MJ Hall
  • FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX)
    L Dahan, JM Phelip, KL Malicot, N Williet, J Desrame, J Volet
  • Opportunity costs of receiving palliative chemotherapy for metastatic pancreatic ductal adenocarcinoma
    EM Bangee
  • Abstract CT234: A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2
    T Karasic
  • Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): a phase 2 trial
    A Kasi, P Chalise, SK Williamson, JC Baranda, W Sun, RMT Al-Rajabi
  • Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
    B Kaufman, R Shapira-Frommer, RK Schmutzler, MW Audeh, M Friedlander, J Balmaña
  • Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation
    RT Shroff, A Hendifar, RR McWilliams, R Geva, R Epelbaum, L Rolfe
  • Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
    S Loibl, J O’Shaughnessy, M Untch, WM Sikov, HS Rugo, MD McKee
  • Randomized, multicenter, phase II trial of Gemcitabine and Cisplatin with or without Veliparib in patients with pancreas Adenocarcinoma and a Germline BRCA/PALB2 mutation
    EM O’Reilly, JW Lee, M Zalupski, M Capanu, J Park, T Golan
  • Randomized phase III trial of Gemcitabine plus Cisplatin compared with Gemcitabine alone in advanced pancreatic cancer
    V Heinemann, D Quietzsch, F Gieseler, M Gonnermann, H Schönekäs, A Rost
  • Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis
    TF Rebelatto, M Falavigna, M Pozzari, F Spada, CA Cella, A Laffi
  • NCCN guidelines updates: pancreatic cancer
    MA Tempero
  • S0923-7534(20)39971-3
    Mosele F, et al. Recommendations for the use of next generation sequencing